Methods of treatment of myeloproliferative neoplasm

A method of treating a myeloproliferative neoplasm or acute myeloid leukemia in a subject comprising administering to the subject a combination of a therapeutically effective amount of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol having the following formula:

• or a pharmaceutically acceptable salt, solvate, tautomer, stereoisomer, isotopologue, prodrug, metabolite, or a polymorph thereof (COMPOUND 1) and a therapeutically effective amount of a ruxolitinib, wherein the subject harbors a mutant allele of IDH2 and a mutant allele of JAK2.